II期临床-话题@MedSci

#II期临床#

478篇内容 | 2604人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524707, encodeId=9de51524e0774, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, objectType=article, longId=167518, objectId=665116e51869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=665116e51869, replyNumber=0, likeNumber=51, createdTime=2019-06-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=665116e51869, moduleTitle=BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=665116e51869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524706, encodeId=471d1524e062b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, objectType=article, longId=166801, objectId=1b1b16680115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1b16680115, replyNumber=0, likeNumber=95, createdTime=2019-05-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1b16680115, moduleTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1b16680115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524705, encodeId=65661524e052c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据, objectType=article, longId=166545, objectId=dc1716654548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc1716654548, replyNumber=0, likeNumber=76, createdTime=2019-05-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc1716654548, moduleTitle=2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc1716654548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524704, encodeId=af811524e04c2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=罗沙司他全球III期临床研究证实其心血管安全性, objectType=article, longId=166305, objectId=121416630562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121416630562, replyNumber=0, likeNumber=57, createdTime=2019-05-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121416630562, moduleTitle=罗沙司他全球III期临床研究证实其心血管安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121416630562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524703, encodeId=e3031524e032f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, objectType=article, longId=166254, objectId=0b72166254e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b72166254e3, replyNumber=0, likeNumber=71, createdTime=2019-05-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b72166254e3, moduleTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b72166254e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524702, encodeId=10111524e02dd, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, objectType=article, longId=165928, objectId=8d7416592893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7416592893, replyNumber=0, likeNumber=63, createdTime=2019-05-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7416592893, moduleTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7416592893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524701, encodeId=44311524e01a0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, objectType=article, longId=165920, objectId=671e16592080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=671e16592080, replyNumber=0, likeNumber=86, createdTime=2019-05-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=671e16592080, moduleTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=671e16592080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524700, encodeId=ebcd1524e0026, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, objectType=article, longId=165917, objectId=84ae16591e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ae16591e2f, replyNumber=0, likeNumber=63, createdTime=2019-05-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ae16591e2f, moduleTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ae16591e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524699, encodeId=842c152469927, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=71, createdTime=2019-05-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524698, encodeId=ce61152469807, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=53, createdTime=2019-05-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524697, encodeId=2fb6152469e16, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=13, createdTime=2019-04-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524696, encodeId=159515246964f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, objectType=article, longId=164499, objectId=73ff16449919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73ff16449919, replyNumber=0, likeNumber=9, createdTime=2019-04-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73ff16449919, moduleTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73ff16449919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524695, encodeId=cc3d1524695f4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=13, createdTime=2019-04-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524694, encodeId=0895152469487, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, objectType=article, longId=164219, objectId=e04a16421946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e04a16421946, replyNumber=0, likeNumber=0, createdTime=2019-04-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e04a16421946, moduleTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e04a16421946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524693, encodeId=b4491524693ad, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始, objectType=article, longId=164216, objectId=25ad16421626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ad16421626, replyNumber=0, likeNumber=44, createdTime=2019-04-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ad16421626, moduleTitle=针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ad16421626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524692, encodeId=68ca15246929b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, objectType=article, longId=163805, objectId=7958163805a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7958163805a9, replyNumber=0, likeNumber=48, createdTime=2019-04-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7958163805a9, moduleTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7958163805a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524691, encodeId=360d1524691e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=66, createdTime=2019-04-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524690, encodeId=75961524690a4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, objectType=article, longId=161551, objectId=9ed316155121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed316155121, replyNumber=0, likeNumber=53, createdTime=2019-03-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed316155121, moduleTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed316155121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524689, encodeId=974b152468962, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, objectType=article, longId=161507, objectId=c9f516150e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f516150e26, replyNumber=0, likeNumber=89, createdTime=2019-03-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f516150e26, moduleTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9f516150e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524688, encodeId=837c152468824, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=52, createdTime=2019-03-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

BioMarin的血友病基因疗法III期临床达到终点，但其长期效应引起质疑

2019-06-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果

2019-05-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据

2019-05-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

罗沙司他全球III期临床研究证实其心血管安全性

2019-05-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果

2019-05-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

全球III期临床研究：roxadustat的心血管安全性得到证实

2019-05-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性

2019-05-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血

2019-05-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2019-05-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2019-05-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-04-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性

2019-04-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-04-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册

2019-04-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

针对新型免疫检查点CEACAM1的单克隆抗体CM-24与Nivolumab联用的I/II期临床将开始

2019-04-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据

2019-04-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2019-04-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果

2019-03-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败

2019-03-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-03-03

科室
- - 订阅+
  - 更多科室
工具
服务